Mast Therapeutics Inc  

(Public, NYSEMKT:MSTX)   Watch this stock  
Find more results for AMEX:ANX
0.000 (0.00%)
May 27 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.21 - 0.60
Open     -
Vol / Avg. 3,030.00/1.74M
Mkt cap 65.56M
P/E     -
Div/yield     -
EPS -0.25
Shares 192.84M
Beta 1.14
Inst. own 14%
Aug 10, 2016
Q2 2016 Mast Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 10, 2016
Mast Therapeutics Inc Annual Shareholders Meeting (Estimated) - 12:00PM EDT - Add to calendar
May 6, 2016
Q1 2016 Mast Therapeutics Inc Earnings Release
Mar 14, 2016
Mast Therapeutics Inc at ROTH Conference
Mar 14, 2016
Q4 2015 Mast Therapeutics Inc Earnings Release
Mar 7, 2016
Mast Therapeutics Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -86.14% -63.89%
Return on average equity -201.71% -96.53%
Employees 28 -
CDP Score - -


3611 Valley Centre Dr Ste 500
SAN DIEGO, CA 92130-3324
United States - Map
+1-858-5520866 (Phone)
+1-858-5520876 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Mast Therapeutics, Inc. is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options. The Company's segment is engaged in the business of developing therapies for serious or life-threatening diseases. The Company focuses on its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, its lead product candidate. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. The Company's AIR001 is in Phase II clinical development for the treatment of patients with HFpEF.

Officers and directors

Brian M. Culley Chief Executive Officer, Director
Age: 43
Bio & Compensation  - Reuters
Brandi L. Roberts C.P.A Chief Financial Officer, Senior Vice President
Age: 41
Bio & Compensation  - Reuters
R. Martin Emanuele Ph.D Senior Vice President - Development
Age: 60
Bio & Compensation  - Reuters
Gregory D. Gorgas Senior Vice President - Commercial
Age: 52
Bio & Compensation  - Reuters
Edwin L. Parsley Chief Medical Officer & Senior Vice President
Age: 54
Bio & Compensation  - Reuters
Howard C. Dittrich M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Peter S. Greenleaf Independent Director
Age: 45
Bio & Compensation  - Reuters
Matthew Pauls J.D. Independent Director
Age: 45
Bio & Compensation  - Reuters
David A. Ramsay CPA Independent Director
Age: 50
Bio & Compensation  - Reuters